Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Meng Welliver MD PhD
Open to Accrual
To evaluate the safety and tolerability of AMG 232 in combination with standard-dose radiotherapy in STS in two separate patient cohorts (A, extremity or body wall; B, abdomen/pelvis/retroperitoneum)
To determine the maximum tolerated dose/recommended phase II dose (MTD/RP2D) of AMG 232 in combination with radiotherapy
Patients with pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma with size ≥5 cm with the intention to treat curatively. Patients must have sufficient tissue to submit to central laboratory for review as well as for NGS sequencing.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.